---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-324972"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-07-30T12:01:01+00:00"
generated_at: "2026-07-30T12:05:20.497771+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Evommune doses first patient in Phase 2b trial of EVO756 for migraine prophylaxis

## Summary
- First patient dosed in Phase 2b trial of MRGPRX2 inhibitor EVO756 for migraine prophylaxis.
- Global, randomized, double-blind, placebo-controlled, dose-ranging trial with ~330 patients over 12 weeks.
- Top-line data expected in 2027; daily doses up to 100 mg being tested.
- EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) via MRGPRX2.
- Primary endpoint: mean change from baseline in monthly migraine days (MMD).

## SEC filing metadata
- accession: 0001193125-26-324972
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-07-30T12:01:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/0001193125-26-324972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-324972
- JSON: https://secwatch.observer/filing/0001193125-26-324972.json
- Plain text: https://secwatch.observer/filing/0001193125-26-324972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.